工程超分子纳米纤维储存来自一种类似葡萄糖素的-1治疗药物
Weike Chen1, Sijie Xian1, Bernice Webber1
1Department of Chemical & Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana 46556, United States.
ACS nano
|October 29, 2024
概括
研究人员使用自组装开发了一种用于糖尿病和肥胖的新注射疗法. 这种长期治疗,高分子GLP-1受体激进剂 (PA-GLP1),在老鼠中显示持续的血糖降低和体重控制.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 材料科学 材料科学 材料科学
背景情况:
- 糖尿病和肥胖是全球重要的健康问题.
- 葡萄糖类-1 (GLP-1) 受体激活剂是有效的治疗方法,但短半衰期需要经常服用.
- 延长释放配方旨在提高患者的坚持性和治疗便利性.
研究的目的:
- 为了设计一种新的,长效的可注射GLP-1受体激动剂.
- 创建一种超分子配方,以持续释放药物并改善治疗结果.
- 在临床前模型中评估这种新配方的疗效.
主要方法:
- 一个假体自组装基因与GLP-1受体激动剂的整合.
- 形成超分子纳米纤维和水凝,以持续释放.
- 在2型糖尿病的老鼠模型中进行了体外释放研究和体内测试.
主要成果:
- 经过工程设计的高分子GLP-1受体agonist (PA-GLP1) 证明了在体外持续释放数周.
- 一次注射给大鼠,可维持治疗性血清度超过40天.
- PA-GLP1显著降低了血糖水平和体重增加,优于每日注射的西马格卢提德.
结论:
- 高分子纳米纤维储存提供了一个有希望的策略,用于长期的GLP-1受体激动剂治疗.
- 这种方法为2型糖尿病和代谢障碍提供了更方便,更有效的治疗选择.
- 模块化设计可适应其他基于的疗法.
相关概念视频
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
01:25Insulin: Biosynthesis, Chemistry, and Preparation
360
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
360